AstraZeneca wins China approval

AstraZeneca has won approval for its new heart drug Brilinta in China, an increasingly important market for the pharmaceuticals group. China’s state food and drug administration has issued a drug import licence for the product, meaning it will now be available for treating patients with acute coronary syndrome in the country, the company said yesterday. Shares in the firm rose 1.58 per cent, outperforming the general market.